Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease

被引：16

作者：

Choi, David K. ^{[1
,2
]}

Cohen, Nathaniel A. ^{[1
]}

Choden, Tenzin ^{[1
]}

Cohen, Russell D. ^{[1
]}

Rubin, David T. ^{[1
]}

机构：

[1] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA

[2] 5841 S Maryland Ave, MC 0100, Chicago, IL 60637 USA

来源：

INFLAMMATORY BOWEL DISEASES | 2023年 / 29卷 / 10期

关键词：

prior authorization; IBD therapies; biologics; advanced IBD therapies; delays; insurance;

D O I：

10.1093/ibd/izad012

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Lay Summary Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.

引用

页码：1658 / 1661

页数：4

共 10 条

[1]

Annear B., 2021, GOVERNOR APPROVES BI

[2]

[Anonymous], 2021, AMA prior authorization (PA) physician survey

[3] Advocating for Patients With Inflammatory Bowel Disease: How to Navigate the Prior Authorization Process [J].

Bhat, Shubha ;

Zahorian, Toni ;

Robert, Regine ;

Farraye, Francis A. .

INFLAMMATORY BOWEL DISEASES, 2019, 25 (10) :1621-1628

[4] A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease [J].

Cheifetz, Adam S. ;

Abreu, Maria T. ;

Afif, Waqqas ;

Cross, Raymond K. ;

Dubinsky, Marla C. ;

Loftus, Edward V., Jr. ;

Osterman, Mark T. ;

Saroufim, Ariana ;

Siegel, Corey A. ;

Yarur, Andres J. ;

Melmed, Gil Y. ;

Papamichael, Konstantinos .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (10) :2014-2025

[5] Delays Related to Prior Authorization in Inflammatory Bowel Disease [J].

Constant, Brad D. ;

de Zoeten, Edwin F. ;

Stahl, Marisa G. ;

Vajravelu, Ravy K. ;

Lewis, James D. ;

Fennimore, Blair ;

Gerich, Mark E. ;

Scott, Frank, I .

PEDIATRICS, 2022, 149 (03)

[6] Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years - United States, 2015 [J].

Dahlhamer, James M. ;

Zammitti, Emily P. ;

Ward, Brian W. ;

Wheaton, Anne G. ;

Croft, Janet B. .

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2016, 65 (42) :1166-1169

[7] Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study [J].

Dalal, Rahul S. ;

Esckilsen, Scott ;

Barnes, Edward L. ;

Pruce, Jordan C. ;

Marcus, Jenna ;

Allegretti, Jessica R. .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (10) :2399-+

[8] Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease [J].

Ollech, Jacob E. ;

Normatov, Inessa ;

Peleg, Noam ;

Wang, Jingzhou ;

Patel, Shivani A. ;

Rai, Victoria ;

Yi, Yangtian ;

Singer, Jorie ;

Dalal, Sushila R. ;

Sakuraba, Atsushi ;

Cohen, Russell D. ;

Rubin, David T. ;

Pekow, Joel .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (01) :104-110

[9] Refocusing Medication Prior Authorization on Its Intended Purpose [J].

Resneck, Jack S., Jr. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (08) :703-704

[10] Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial [J].

Vermeire, Severine ;

Su, Chinyu ;

Lawendy, Nervin ;

Kobayashi, Taku ;

Sandborn, William J. ;

Rubin, David T. ;

Modesto, Irene ;

Gardiner, Sean ;

Kulisek, Nicole ;

Zhang, Haiying ;

Wang, Wenjin ;

Panes, Julian .

JOURNAL OF CROHNS & COLITIS, 2021, 15 (07) :1130-1141

← 1 →